Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

GlaxoSmithKline PLC Add to portfolio

LON100:GSK, Dec 11, 04:57 UTC

Latest LON100:GSK News

Filter your feed

Apply Filter

Sunday, December 09


News

Should you buy the GSK share price after last week’s 10% fall?

GSK

Should you buy the GSK share price after last week’s 10% fall? Fool.co.uk9 December 2018, 11:00 GMT. Until last week, 2018 had looked like being a good year for GlaxoSmithKline (LSE: GSK) shareholders. A surprise twist. However, the Horlicks announcement was followed less than four hours later by news that the firm had agreed to spend $5.1bn (£4bn) buying US pharma firm Tesaro. Between 2018 and 2020, “the acquisition of Tesaro and associated R&D and commercial investments” are expected to reduce Glaxo’s adjusted earnings by “mid-to-high single-digit percentages”. As a result, the firm has downgraded its guidance for the 2016-20 period.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, December 07


News

Analysts Outlook: Glaxosmithkline Plc (GSK)Expert Gazette

GSK GSK

Glaxosmithkline Plc (NYSE:GSK) shares traded -2.4% down during most recent session to reach at the closing price of $37.42. The stock exchanged hands 6.25 Million shares versus average trading capacity of 2.91 Million shares, yielding a market cap of $92 Billion. Taking a broader look brokerage firms’ analysts on the street with an expectant view have Glaxosmithkline Plc (NYSE:GSK) high price target of $45 and with a conservative view have low price target of $42. Additionally on 8/20/18 Argus “Maintained” Glaxosmithkline Plc (NYSE:GSK) to Buy setting price target at $47 and on 10/26/17 Bank of America “Downgrades” the stock to Neutral.

Read Full Details

Topics:
  • Business
  • Financial
News

GlaxoSmithKline (GSK) Earns “Hold” Rating from Kepler Capital Markets – XNewsPress

DBK GSK +1 more DBK GSK GSK

Several other equities analysts have also recently issued reports on GSK. Finally, Jefferies Financial Group set a GBX 1,775 ($23.19) target price on shares of GlaxoSmithKline and gave the company a buy rating in a research note on Thursday, August 16th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($16.14) and a 52-week high of GBX 1,724.50 ($22.53).

Read Full Details

Topics:
  • Business
  • Financial
  • Health
News

Barclays Lowers GlaxoSmithKline (GSK) to Equal Weight – XNewsPress

GSK GSK

Zacks Investment Research raised GlaxoSmithKline from a hold rating to a buy rating and set a $45.00 price target on the stock in a research report on Wednesday, November 28th. The company presently has an average rating of Hold and a consensus target price of $41.79. The firm has a market cap of $95.08 billion, a price-to-earnings ratio of 12.99, a price-to-earnings-growth ratio of 2.57 and a beta of 0.81. Optimum Investment Advisors now owns 2,749 shares of the pharmaceutical company’s stock valued at $110,000 after buying an additional 1,291 shares during the period.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Thinking of buying the GlaxoSmithKline share price? Read this first

ULVR UNA +2 more ULVR UNA GSK GSK

Shares in global healthcare company GlaxoSmithKline(LSE: GSK) have dived by nearly 13% over the past two weeks. Earlier this year, Glaxo paid around £9bn to buy out the stake of Swiss rival Novartis in its consumer healthcare business, which gave Glaxo full ownership of the joint venture but added significantly to the group’s borrowings. FTSE 100 consumer goods giant Unilever recently agreed to buy this business for a total of $3.8bn, which the market applauded. However, only a few days after this deal was announced, Glaxo revealed that it is going to spend all of the proceeds from the Unilever deal (and more) buying oncology-focused US pharma business Tesaro Inc for $5.1bn. At the time of writing, this is equivalent to a dividend yield of 5.6%. However, the total distribution is consuming around £4bn of free cash flow every year. For the past five years, the company has produced an annualised free cash flow of around £4.5bn, leaving almost nothing to pay down debt. So far, management has been able to balance Glaxo’s obligations so that it can maintain the dividend at 80p, but to me, it looks as if the group is increasingly running out of breathing room.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, December 06


News

Fimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract Infections

GSK

ST. LOUIS, Dec. 6, 2018 /PRNewswire/ -- Fimbrion Therapeutics, Inc. announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). This novel drug candidate represents a new strategy for treating bacterial infections by preventing the bacteria that cause UTIs from sticking to the walls of the bladder, thus allowing the body to naturally eliminate the infection. Since this mannose-containing compound does not kill bacteria, it potentially could treat and prevent UTIs without inducing antibiotic resistance. "We are thrilled to have hit this candidate selection milestone with GSK," Dr. Scott Hultgren, co-founder and board member of Fimbrion, said. About DPAC - Discovery Partnerships with Academia (DPAc) is an innovative approach to drug discovery. As a unit within GSK's research and development organization, DPAc is dedicated to creating highly collaborative relationships with leading academic researchers to develop new medicines that truly benefit patients.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

GlaxoSmithKline (GSK) Downgraded by Barclays to “Equal weight” – Fairfield Current

GSK GSK

A number of other equities research analysts also recently weighed in on GSK. Deutsche Bank reaffirmed a hold rating and set a GBX 1,525 ($19.93) price objective on shares of GlaxoSmithKline in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($16.14) and a 12-month high of GBX 1,724.50 ($22.53).

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

GlaxoSmithKline (GSK) PT Set at GBX 1,620 by Cfra – PressOracle

GSK GSK +3 more GSK GSK HSBA 0005 HSBC

Cfra’s price target indicates a potential upside of 13.27% from the company’s previous close. GSK has been the topic of several other research reports. Societe Generale set a GBX 1,000 ($13.07) target price on shares of GlaxoSmithKline and gave the stock a “sell” rating in a report on Monday, September 10th. GlaxoSmithKline has a twelve month low of GBX 1,235.20 ($16.14) and a twelve month high of GBX 1,724.50 ($22.53). The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read Full Details

Topics:
  • Business
  • Financial
News

GlaxoSmithKline (GSK) Given a GBX 1,600 Price Target by Credit Suisse Group Analysts – XNewsPress

GSK GSK +2 more GSK GSK VOD VOD

Credit Suisse Group’s price objective would suggest a potential upside of 10.22% from the company’s current price. Goldman Sachs Group set a GBX 1,900 ($24.83) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a report on Wednesday, October 31st. Societe Generale set a GBX 1,000 ($13.07) price objective on shares of GlaxoSmithKline and gave the company a “sell” rating in a report on Monday, September 10th. The company has a consensus rating of “Hold” and a consensus target price of GBX 1,518.84 ($19.85). GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($16.14) and a 1-year high of GBX 1,724.50 ($22.53).

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, December 05


News

GlaxoSmithKline’s (GSK) Hold Rating Reaffirmed at Kepler Capital Markets – Fairfield Current

GSK GSK

Kepler Capital Markets restated their hold rating on shares of GlaxoSmithKline (LON:GSK) in a report published on Tuesday morning. Goldman Sachs Group set a GBX 1,900 ($24.83) price target on shares of GlaxoSmithKline and gave the stock a buy rating in a research note on Wednesday, October 31st. Societe Generale set a GBX 1,000 ($13.07) price target on shares of GlaxoSmithKline and gave the stock a sell rating in a research note on Monday, September 10th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline presently has an average rating of Hold and an average target price of GBX 1,518.84 ($19.85).

Read Full Details

Topics:
  • Business
  • Financial